Cymbalta (duloxetine) sign now

Cymbalta Petition

We the individuals listed below have electronically signed this petition for the purpose of making it known that consumers treated with the SSNRI antidepressant Cymbalta have or are experiencing "often ignored" serious side effects of this medication.

Thousands of patients in the US and worldwide are unable to discontinue Cymbalta or even reduce dosage due to the rapid onset of severe withdrawal-like symptoms which often initiates before a patient begins dose reduction due to the short half-life of Cymblata.

Documentation by Eli Lilly of discontinuation effects from Cymbalta were not studied for longer than 9 weeks of drug administration, much shorter than most most patients take the drug.

Furthermore, the study on discontinuation only studied abrupt discontinuation, and the manufacturer gives no details to the practitioner prescribing Cymbalta on how to properly taper the drug in order to minimize withdrawals beyond ambiguously stating "whenever possible, clinicians gradually reduce the dose no less than 2 weeks before discontinuation of duloxetine treatment."

Futhermore this study indicates that more than 35\% of these discontinuation adverse effects lasted longer than one week, but no followup study for these patients was published stating how long these adverse effects ultimately persisted for, again leaving doctors and patients at a loss for information.

*Perahia DG, Kajdasz DK, Desaiah D, Haddad PM. "Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder". J Affect Disord. 2005 Dec;89(1-3):207-12. Epub 2005 Nov 2.

Cymbalta as prescribed to us by our doctors resulted in anxiety and agitation, sexual dysfunction, hypomania, weight gain, orthostatic hypotension, "brain zaps" (or electric like sensations in the head), high blood pressure and pulse rate, insomnia and bizarre vivid nightmares, thoughts of suicide, paresthesia, deterioration in eyesight, akathisia, dehydrating night sweats, memory problems, thyroid disorders which can cause the very depression this medication was first prescribed to treat, among other serious side effects.

These adverse effects are lasting up to 18 months in some patients. The effects are often felt after the post acute withdrawal period as well, indicating an electrophysiological dependence on the drug.

These iatrogenic effects were ignored or underplayed by its manufacturer and the FDA, which resulted in our overall inability to function normally for lengthy periods of time during usage and attempted dose reduction.

Patients accepting treatment with Cymbalta are not being forewarned that by their use of Cymblata -- sleeping medication, blood pressure medication, and anti-anxiety medication might become a concurrent necessity. Thus the mis-informed consumer totally unexpectedly finds themselves being prescribed many more drugs than they ever anticipated needing in order to overcome withdrawal syndrome incurred by Cymbalta use.

We all know that taking prescription medication involves some risks and that with each medication some percentage of patients are likely to experience adverse results. We strongly feel however, that the risks involved with the usage of Cymbalta is greater than the medical community and the public realize, certainly greater than we were ever told, and that Eli Lilly and the FDA knew of these risks but failed to communicate those risks to the consumer and their physicians.

The French journal Prescrire International stated the opinion "In practice, duloxetine currently has no place in the treatment of depression or diabetic neuropathy. Its efficacy has not yet been demonstrated to be even equivalent to that of other available drugs, and it has too many adverse effects, given this degree of uncertainty."

*"Duloxetine: new indication. Depression and diabetic neuropathy: too many adverse effects.". Prescrire International. (2006 Oct;15(85):168-72)

In its two year life span Cymbalta has already been indicated of mortality in multiple drug use, cases of serotonin syndrome, dyskinesia, and suicide. All of these scenarios have been published by licensed medical professionals, and are likely only a sample of the actual amount of cases.

We believe the opinion of the French journal Prescrire International will be assumed by many more medical professionals as Cymbalta stays on the market longer.

Cymbalta is also being sold for the use of diabetic neuropathy, but the lead researcher in these trials for Eli Lilly for use of Cymblata for diabetic neuropathy, Michael Detke, has stated that "Duloxetine is not effective for the numbness or tingling, nor is it effective for the other complications of diabetes. It does not treat the underlying nerve damage, but can help reduce the pain". This is not stated in the packaging information for Cymbalta and is intellectually dishonest.

Furthermore the weight gain that is often associated with Cymbalta use puts diabetics in risk of further complicating their disease.

In the absence of peer-reviewed comparative trials of Cymbalta there is a doubt to the efficacy and safety of Cymbalta. It is therefore not possible to know whether Cymblata is as effective or safe as other antidepressants.

Our lives have been negatively, unexpectedly, and undeservingly impacted by the antidepressant Cymblata. We were not given full disclosure of this medication's known adverse effects, and many of us suffered greatly because of this failure to warn. Therefore, our purpose with this petition is to share information that we have gathered so that others will have adequate knowledge and be able to fully discuss options and risks of the use of Cymbalta with qualified medical professionals before they make any final choice regarding initiating these types of medications. Thereby being able to be a knowledgeable consumer and make the appropriate decisions together with their physicians in regards to their own medical treatment and might be spared the suffering we have experienced first hand.

By this petition let it be made clear that we are not advocating the non-use of Cymblata because this medication's possible benefits to the public at large is beyond our scope of knowledge to the extent that each individual now considering the use of Cymbalta has informational benefits we did not, now that more medical information regarding Cymbalta has been released to the public.

As individuals, and their are a significant number of us, we have found that the disclosure regarding the side effects and efficacy of Cymblata that we were given and which is still being propagated, is significantly misleading to the consumer and the medical community at large. This cannot continue and we hope you will support us with our pleas to Eli Lilly and the Food and Drug Administration for full and accurate disclosure.

Sign The Petition


If you already have an account please sign in, otherwise register an account for free then sign the petition filling the fields below.
Email and the password will be your account data, you will be able to sign other petitions after logging in.

Privacy in the search engines? You can use a nickname:

Attention, the email address you supply must be valid in order to validate the signature, otherwise it will be deleted.

I confirm registration and I agree to Usage and Limitations of Services

I confirm that I have read the Privacy Policy

I agree to the Personal Data Processing


Who signed this petition saw these petitions too:

Sign The Petition


If you already have an account please sign in


I confirm registration and I agree to Usage and Limitations of Services

I confirm that I have read the Privacy Policy

I agree to the Personal Data Processing

0 / 50

Latest Signatures

No one has signed this petition yet

Keith BradshawBy:
Petition target:
Eli Lilly, Food and Drug Administration


No tags


Invite friends from your address book

Embed Codes

direct link

link for html

link for forum without title

link for forum with title